Welcome to LookChem.com Sign In|Join Free
  • or
2-chloro-N-(3-ethynylphenyl)pyrimidin-4-amine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1403933-74-3

Post Buying Request

1403933-74-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1403933-74-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1403933-74-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,3,9,3 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1403933-74:
(9*1)+(8*4)+(7*0)+(6*3)+(5*9)+(4*3)+(3*3)+(2*7)+(1*4)=143
143 % 10 = 3
So 1403933-74-3 is a valid CAS Registry Number.

1403933-74-3Relevant academic research and scientific papers

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors

Liang, Xuewu,Zang, Jie,Zhu, Mengyuan,Gao, Qianwen,Wang, Binghe,Xu, Wenfang,Zhang, Yingjie

, p. 950 - 955 (2016)

Abnormalities in the JAK/STAT signaling pathway lead to many diseases such as immunodeficiency, inflammation, and cancer. Herein, we designed and synthesized a series of 4-amino-(1H)-pyrazole derivatives as potent JAKs inhibitors for cancer treatment. Res

ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS

-

Paragraph 0040; 0042, (2014/04/03)

A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

Chen, Kuen-Feng,Pao, Kuan-Chuan,Su, Jung-Chen,Chou, Yi-Chieh,Liu, Chun-Yu,Chen, Hui-Ju,Huang, Jui-Wen,Kim, Inki,Shiau, Chung-Wai

, p. 6144 - 6153 (2012/11/07)

Cancerous inhibitor of PP2A (CIP2A) is a novel human oncoprotein that inhibits PP2A, contributing to tumor aggressiveness in various cancers. Several studies have shown that downregulation of CIP2A by small molecules reduces PP2A-dependent phosphorylation of Akt and induces cell death. Here, a series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma were evaluated. The di-substituted quinazoline and pyrimidine derivatives were more potent inhibitors of cancer-cell proliferation than the mono-substituted derivatives. In particular, compound 1 with chloride at position 2 of quinazoline was as potent as erlotinib in inducing cell death but no inhibition for EGFR activity. Further assays confirmed a correlation between cell death, and CIP2A and Akt inhibition by these derivatives. Among all the derivatives, compounds 19 and 22 showed the most potent antiproliferative activities and the strongest inhibition of CIP2A and p-Akt expression.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1403933-74-3